X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (355) 355
Conference Proceeding (40) 40
Publication (33) 33
Book Review (23) 23
Patent (15) 15
Book Chapter (2) 2
Dissertation (2) 2
Book / eBook (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (175) 175
index medicus (168) 168
humans (161) 161
female (145) 145
breast cancer (110) 110
middle aged (108) 108
aged (97) 97
adult (94) 94
breast neoplasms - drug therapy (83) 83
cancer (81) 81
breast neoplasms - pathology (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
chemotherapy (46) 46
tumors (42) 42
trastuzumab (41) 41
treatment outcome (40) 40
care and treatment (39) 39
life sciences (39) 39
prognosis (39) 39
aged, 80 and over (37) 37
metastasis (37) 37
breast neoplasms - metabolism (36) 36
survival (35) 35
therapy (34) 34
male (31) 31
antineoplastic combined chemotherapy protocols - adverse effects (30) 30
breast neoplasms - genetics (29) 29
clinical trials (29) 29
disease-free survival (29) 29
medicine & public health (29) 29
research (28) 28
antineoplastic agents - therapeutic use (27) 27
neoplasm staging (27) 27
receptor, erbb-2 - metabolism (27) 27
analysis (25) 25
breast neoplasms - mortality (25) 25
hematology, oncology and palliative medicine (24) 24
neoplasm metastasis (22) 22
health aspects (21) 21
expression (20) 20
genetic aspects (20) 20
epidermal growth factor (19) 19
metastatic breast cancer (19) 19
paclitaxel (19) 19
postmenopausal women (19) 19
cancer therapies (18) 18
erbb-2 protein (18) 18
[ sdv.can ] life sciences [q-bio]/cancer (17) 17
animals (17) 17
antineoplastic agents (17) 17
estrogen (17) 17
gene expression (17) 17
kaplan-meier estimate (17) 17
metastases (17) 17
patients (17) 17
pharmacology & pharmacy (17) 17
young adult (17) 17
carcinoma (16) 16
everolimus (16) 16
resistance (16) 16
women (16) 16
biomarkers, tumor - metabolism (15) 15
combination (15) 15
drug therapy (15) 15
endocrine therapy (15) 15
fluorouracil - administration & dosage (15) 15
investigating or analysing materials by determining theirchemical or physical properties (15) 15
measuring (15) 15
mutation (15) 15
physics (15) 15
receptors, estrogen - metabolism (15) 15
receptors, progesterone - metabolism (15) 15
survival rate (15) 15
testing (15) 15
antimitotic agents (14) 14
antineoplastic agents - adverse effects (14) 14
cancer research (14) 14
docetaxel (14) 14
her2 (14) 14
sirolimus - analogs & derivatives (14) 14
adjuvant chemotherapy (13) 13
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
capecitabine (13) 13
chemotherapy, adjuvant (13) 13
disease progression (13) 13
double-blind (13) 13
drug administration schedule (13) 13
gene expression regulation, neoplastic (13) 13
postmenopause (13) 13
survival analysis (13) 13
taxoids - administration & dosage (13) 13
antibodies, monoclonal, humanized (12) 12
brain neoplasms - drug therapy (12) 12
development and progression (12) 12
double-blind method (12) 12
immunohistochemistry (12) 12
medical prognosis (12) 12
oncology, experimental (12) 12
receptor (12) 12
research article (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Cancer, ISSN 0007-0920, 07/2018, Volume 119, Issue 1, pp. 133 - 134
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1324 - 1334
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 461 - 471
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 724 - 734
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 07/2018, Volume 119, Issue 1, pp. 133 - 134
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 375 - 384
Journal Article